MISSISSAUGA, 28 April, 2017
Roche Canada Commends the Ontario Government on its Investment in Healthcare and Access to Medicines
The Ontario Liberal government announced its 2017 budget yesterday with a significant investment in healthcare, including a 8.4% increase in the drug budget and the creation of OHIP+, which as of January 1, 2018 will provide drug coverage to all Ontarians under the age of 24, with no deductibles or co-pays.
“We congratulate Minister Sousa and the Liberal government for its demonstrated commitment to the health and wellbeing of Ontarians. We strongly support programs that are focused on ensuring patients have timely and fair access to medicines and we look forward to working with the government to provide the best possible outcomes for patients”, said Ronnie Miller, President and CEO of Hoffmann-La Roche Limited (Roche Canada).
Headquartered in Basel, Switzerland, Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
In 2016, the Roche Group employed more than 94,000 people worldwide, invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Roche Canada was founded in 1931. The company employs almost 900 people across the country, with its pharmaceuticals head office located in Mississauga, Ontario, and diagnostics division based in Laval, Quebec. Roche Canada is actively involved in local communities, investing in charitable organizations and partnering with healthcare institutions across the country. For more information, visit www.rochecanada.com.
- end -
For more information, please contact: